Clinical trials: BD
Advanced Solid Tumours
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
This is a 2 parts phase I, open label trial of olaparib monotherapy and olaparib in combination with paclitaxel in patients with solid tumours.
- Trial name
- NCT02430311
- Testing
- Olaparib, Paclitaxel
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Catheter Related Complication, Vascular Access Site Management
A Post-Market Clinical Follow Up Study to Evaluate BD PureHub™ Disinfecting Cap Use on Needle-Free Connectors
The study will collect use data of the Becton Dickinson (BD) PureHub™ Disinfecting Cap in combination with needle-free connectors, which are attached to vascular access devices (VAD).
- Conditions
- Catheter Related Complication, Vascular Access Site Management, Disinfecting Cap
- Trial name
- NCT05130762
- Testing
- BD PureHub™ Disinfecting Cap Placements: Attachments/removals
- Where
- 5 sites in Austria, Belgium and 2 more
- Volunteers
- 157 people
- Sponsor
- Becton, Dickinson and Company
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Breast Cancer
A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers
This Phase I clinical study is designed to evaluate the safety and determine the maximum tolerated dose (MTD) of Orialpha (BD-C) in healthy adult volunteers.
- Trial name
- NCT07300202
- Testing
- Orialpha (BD-C) at 0.25 x anticipated therapeutic dose, Orialpha (BD-C) at 0.5 x anticipated therapeutic dose, Orialpha (BD-C) at the anticipated therapeutic dose
- Where
- Vietnam
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oriplantee Company Limited
Asthma
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma
- Trial name
- NCT00461500
- Testing
- Salmeterol xinafoate/fluticasone propionate combination, Fluticasone propionate
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units
The primary purpose of this study is to demonstrate that the BD 4mm x 32G Ultra-Fine Nano pen needle provides equivalent glycemic control to the BD 8mm x 31G Ultra-Fine short pen needle as measured by fructosamine (FRU) among…
- Trial name
- NCT01334606
- Testing
- 4 mm x 32G pen needle (Nano), 8mm x 31G pen needle (Short)
- Where
- 3 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Becton, Dickinson and Company
Catheters, Catheterization, Peripheral
Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED
A randomized prospective comparison of two FDA approved intravenous catheters in the emergency department setting. The Terumo SurFlash Plus offers novel technologies that promise to increase intravenous access success rates and…
- Trial name
- NCT02769442
- Testing
- Terumo SurFlash Plus catheter, BD Insyte Autoguard catheter
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Maryland, Baltimore
Bipolar Disorder, Medication Adherence
CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)
This is a prospective study using customized adherence enhancement (CAE) and long-acting injectable (LAI) antipsychotic in 30 individuals with bipolar disorder (BD) at risk for treatment non-adherence.
- Conditions
- Bipolar Disorder, Medication Adherence, Medication Non Adherence
- Trial name
- NCT03408873
- Testing
- Abilify Maintena, Customized Adherence Enhancement (CAE)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Martha Sajatovic
Diabetes
Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle
This is a subject single blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. the thinner commercially available Terumo Nanopass® pen needle.
- Trial name
- NCT03878745
- Testing
- Terumo Nanopass® 34G pen needle, BD Nano™ PRO 32G pen needle
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Becton, Dickinson and Company
Rheumatoid Arthritis
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.
- Trial name
- NCT01890473
- Testing
- Abatacept
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Bipolar Disorder
12- Week Open Label Treatment of Refractory Bipolar Depression
1. Determine the change in symptomatology and function in refractory bipolar depression, when treated with combination of DEP+AZP for a period of 12 weeks 2.
- Trial name
- NCT00223496
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Substance Use Disorders
Benzodiazepine Discontinuation in Opioid Agonist Therapy
The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy who currently use benzodiazepines.
- Trial name
- BZD-OAT (NCT04109118)
- Testing
- Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), BZD discontinuation protocol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston Medical Center
Anesthesia, Analgesia
Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories.
Multi-center, prospective, open label, single arm post-market study to assess the real-world safety and efficacy of BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes used in an on-market…
- Trial name
- NCT05953363
- Testing
- BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes
- Where
- 5 sites in Austria, Germany and 1 more
- Volunteers
- 161 people
- Sponsor
- Becton, Dickinson and Company
Wilson's Disease
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
A randomised, open-label study evaluating the pharmacokinetics, safety, and tolerability of a new once daily dose of 900mg of TETA 4HCL by comparing it against the current marketed Cuprior® formulation (450mg trientine base…
- Trial name
- NCT06128954
- Testing
- 900mg TETA 4HCl Once Daily Formulation, 900mg TETA 4HCl Cuprior®
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Orphalan
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control Among Diabetics Using Three Different Pen Needles
Anxiety about needles is a commonly expressed concern by diabetics about beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of currently marketed pen needles may…
- Trial name
- NCT00928057
- Testing
- 4mm x 32G pen needle, 8mm x 31G pen needle, 5mm x 31G pen needle
- Where
- 4 sites in United States
- Volunteers
- 173 people
- Sponsor
- Becton, Dickinson and Company